Waldenstrom's macroglobulinaemia

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
6 Unique sponsors
6 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
L Oncology (ATC L) 3
Mechanism of action (INN-stem analysis)
Proteasome inhibitor 2 substances
BTK inhibitor 1 substance
Monoclonal antibody (chimeric) 1 substance
BCL-2 inhibitor 1 substance
Monoclonal antibody 1 substance
Phase II: 4 Phase I/II: 1 Phase IV: 1 Phase I (First in Human): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase II

4 trials
  • French Innovative Leukemia Organization Commercial
    IMP not specified
    2023-505781-28-00 1 country 2026 n=102
    Recruiting
  • Universitaetsklinikum Ulm AöR Academic
    CARFILZOMIB; IBRUTINIB
    2024-511929-60-00 3 countries 2021 n=105
    Ended
  • University Hospital Of Ulm AöR Academic
    RITUXIMAB; VENETOCLAX
    2022-500574-34-00 2 countries 2025 n=55
    Recruiting
  • University Hospital Of Ulm AöR Academic
    BORTEZOMIB; IBRUTINIB; RITUXIMAB
    2022-500584-12-00 2 countries 2019 n=53
    Ended

Phase I/II

1 trial
  • Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic
    EPCORITAMAB
    2025-522295-91-00 3 countries n=28 Orphan
    Pending

Phase IV

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IBRUTINIB
    2023-507329-40-00 7 countries 2017 n=125
    Ended

Phase I (First in Human)

1 trial
  • BeOne Medicines AG Commercial
    IMP not specified
    2022-502157-33-00 5 countries 2023 n=239
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
University Hospital Of Ulm AöR Academic 2 Phase II 1
French Innovative Leukemia Organization Commercial 1 Phase II 1
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase IV 0
BeOne Medicines AG Commercial 1 Phase I (First in Human) 1
Universitaetsklinikum Ulm AöR Academic 1 Phase II 0
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic 1 Phase I/II 0
New trials by year
2019
1
2021
1
2023
1
2025
1
2026
1
← All indication landscapes